| Host: |
HEK293 cells |
| Reactivity: |
Human |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Recombinant-Human IL-1 Rrp2/IL-1 R6-C-hFc protein was developed from hek293 cells and has a target region of C-hFc. For use in research applications. |
| Formulation: |
Lyophilized from a 0.22 Mu m filtered solution of PBS, pH 7.4. |
| Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Gene Symbol: |
IL1RL2 |
| Gene ID: |
8808 |
| Uniprot ID: |
ILRL2_HUMAN |
| Immunogen Region: |
Asp20-Arg335 |
| Immunogen: |
Recombinant Human IL-1 Rrp2/IL-1 R6 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Asp20-Arg335) of human IL-1 Rrp2/IL-1 R6 (Accession #NP_003845.2) fused with a hFc tag at the C-terminus. |
| Function | Receptor for interleukin-36 (IL36A, IL36B and IL36G). After binding to interleukin-36 associates with the coreceptor IL1RAP to form the interleukin-36 receptor complex which mediates interleukin-36-dependent activation of NF-kappa-B, MAPK and other pathways. The IL-36 signaling system is thought to be present in epithelial barriers and to take part in local inflammatory response.it is similar to the IL-1 system. Seems to be involved in skin inflammatory response by induction of the IL-23/IL-17/IL-22 pathway. |
| Protein Name | Interleukin-1 Receptor-Like 2Il-36 ReceptorIl-36rInterleukin-1 Receptor-Related Protein 2Il-1rrp2Il1r-Rp2 |
| Database Links | Reactome: R-HSA-9007892Reactome: R-HSA-9014826 |
| Cellular Localisation | MembraneSingle-Pass Type I Membrane Protein |
| Alternative Protein Names | Interleukin-1 Receptor-Like 2 proteinIl-36 Receptor proteinIl-36r proteinInterleukin-1 Receptor-Related Protein 2 proteinIl-1rrp2 proteinIl1r-Rp2 proteinIL1RL2 proteinIL1RRP2 protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
